Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences, Inc. (Nasdaq: CSTL) has appointed Kim Caple and Ellen Goldberg to its board of directors, effective immediately. Derek Maetzold, CEO, expressed confidence in their leadership and experience. Caple, currently with Thermo Fisher Scientific, brings expertise in genetic analysis technologies. Goldberg, founder of CHORD Consulting, has a robust background in diagnostics and marketing, notably with the Oncotype DX Breast Cancer Assay. The company specializes in dermatologic diagnostics, providing genomic information for better treatment decisions.
Castle Biosciences, Inc. (Nasdaq: CSTL) has been recognized in the Houston Chronicle’s CHRON 100 list for the second consecutive year, highlighting its success in Market Value, Market Return, and Revenue Growth. The recognition reflects Castle's ongoing growth in genomic diagnostics for dermatologic conditions, primarily through its flagship product, the DecisionDx®-Melanoma. The firm plans to enhance its diagnostic suite further, contributing to its stature as a leader in the sector and aiming to improve patient outcomes.
Castle Biosciences, Inc. (Nasdaq: CSTL) has received approval from the New York State Department of Health for its DecisionDx-SCC test, a gene expression profile test that predicts the risk of cutaneous squamous cell carcinoma metastasis. This approval allows patients in New York access to the test, enhancing informed treatment decisions. The company continues to expand its range of genomic tests, having previously gained approvals for others, and emphasizes its commitment to high standards in laboratory medicine.
Summary not available.
AltheaDx has appointed Derek Maetzold to its Board of Directors, enhancing its leadership with expertise in diagnostics and management. Maetzold, CEO of Castle Biosciences (CSTL), has significant experience in growing molecular diagnostics businesses. His addition aims to drive AltheaDx’s growth strategy, especially in the demand for pharmacogenomics testing for mental health, intensified by the pandemic. AltheaDx's flagship product, NeuroIDgenetix, is a Medicare-reimbursed test that enhances clinical decision-making for anxiety and depression treatments.
Castle Biosciences (Nasdaq: CSTL) announces a ribbon-cutting ceremony for its new headquarters in Friendswood, Texas, on May 25, 2021, from 3:00 p.m. to 6:00 p.m. Central time. The expansion reflects the company's commitment to improving patient care in dermatology, particularly for skin cancer. In 2020, the workforce grew by nearly 50%, with further hiring expected in 2021. The new facility will support the company's growth and development of genomic tests, including DecisionDx series for various skin cancers. Castle aims to enhance its offerings in dermatologic diagnostics.
Castle Biosciences (Nasdaq: CSTL) announced a collaboration with the American Skin Association to fund melanoma research. The ASA Castle Biosciences Research Grant was awarded to Dr. Joel Sunshine of Johns Hopkins for his study on 'mRNA Nanoparticle Vaccination for Melanoma Immunotherapy.' CEO Derek Maetzold emphasized the company's commitment to advancing dermatologic disease treatments. ASA has funded over $50 million in melanoma research, underscoring its long-standing dedication to skin disease advancements.
Castle Biosciences (Nasdaq: CSTL) announced a publication in the Journal of Drugs in Dermatology detailing the integration of its DecisionDx-SCC gene expression profiling test into clinical practice for squamous cell carcinoma (SCC). The study emphasizes that DecisionDx-SCC is a significant predictor of metastatic risk, surpassing traditional staging methods. Key points include its utility in nodal evaluation, adjuvant radiation therapy, and surveillance, potentially improving treatment decisions and reducing unnecessary procedures. The company aims to enhance personalized care for high-risk SCC patients.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced participation in the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021. CEO Derek Maetzold and CFO Frank Stokes will deliver a pre-recorded investor presentation and hold virtual one-on-one meetings. The presentation will be accessible on the conference site and Castle's website from May 26 to June 16, 2021. Castle specializes in personalized genomic information for dermatologic diagnostics, offering tests for various skin cancers and conditions.
Castle Biosciences (Nasdaq: CSTL) has appointed Tiffany Olson to its board of directors, effective immediately. Olson, who has extensive experience in public diagnostics, is expected to enhance the company’s strategic direction. Currently the president of Nuclear & Precision Health Solutions at Cardinal Health, Olson previously held leadership roles at NaviMed and Roche Diagnostics. She is recognized for her contributions to personalized medicine and has received several awards. Her appointment aims to strengthen Castle's board with her insights into high-growth operations.